Development of vaccines against Burkholderia pseudomallei

Frontiers in Microbiology

Volumn 2, Issue SEP, 2011, Pages

  Patel, Natasha ^a   Conejero, Laura ^a   De Reynal, Melanie ^a   Easton, Anna ^b   Bancroft, Gregory J ^a   Titball, Richard W ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Burkholderia pseudomallei; Melioidosis; Vaccines

Indexed keywords

ANIMALIA; BURKHOLDERIA PSEUDOMALLEI; NEGIBACTERIA;

EID: 84860827887     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2011.00198     Document Type: Review

References (173)

1. Adler, N. R., Govan, B., Cullinane, M., Harper, M.,Adler,B., and Boyce, J. D. (2009). The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease? FEMS Microbiol. Rev. 33, 1079-1099.
2. Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and innate immunity. Cell 124, 783-801.
3. Anuntagool, N., Intachote, P., Wuthiekanun, V., White, N. J., and Sirisinha, S. (1998). Lipopolysaccharide from nonvirulent Ara+Burkholderia pseudomallei isolates is immunologically indistinguishable from lipopolysaccharide from virulent Ara-clinical isolates. Clin. Diagn. Lab. Immunol. 5, 225-229.
4. Ashdown, L. R., and Guard, R. W. (1984). The prevalence of human melioidosis in Northern Queensland. Am. J. Trop. Med. Hyg. 33, 474-478.
5. Atkins, T., Prior, R. G., Mack, K., Russell, P., Nelson, M., Oyston, P., Dougan, G., and Titball, R. W. (2002a). A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect. Immun. 70, 5290-5294.
6. Atkins, T., Prior, R., Mack, K., Russell, P., Nelson, M., Prior, J., Ellis, J., Oyston, P. C. F., Dougan, G., and Titball, R. W. (2002b). Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J. Med. Microbiol. 51, 539-553.
7. Bangari, D. S., and Mittal, S. K. (2006). Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24, 849-862.
8. Barnes, J. L., and Ketheesan, N. (2007). Development of protective immunity in a murine model of melioidosis is influenced by the source of Burkholderia pseudomallei antigens. Immunol. Cell Biol. 85, 551-557.
9. Barnes, J. L., Ulett, G. C., Ketheesan, N., Clair, T., Summers, P. M., and Hirst, R. G. (2001). Induction of multiple chemokine and colony-stimulating factor genes in experimental Burkholderia pseudomallei infection. Immunol. Cell Biol. 79, 490-501.
10. Barnes, J. L., Warner, J., Melrose, W., Durrheim, D., Speare, R., Reeder, J. C., and Ketheesan, N. (2004). Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. Clin. Immunol. 113, 22-28.
11. Bernatoniene, J., and Finn, A. (2005). Advances in pneumococcal vaccines: advantages for infants and children. Drugs 65, 229-255.
12. Bhattacharjee, A. K., Izadjoo, M. J., Zollinger, W. D., Nikolich, M. P., and Hoover, D. L. (2006). Comparison of protective efficacy of sub-cutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide sub-unit vaccine. Infect. Immun. 74, 5820-5825.
13. Breitbach, K., Klocke, S., Tschernig, T., van Rooijen, N., Baumann, U., and Steinmetz, I. (2006). Role of inducible nitric oxide synthase and NADPH oxidase in early control of Burkholderia pseudomallei infection in mice. Infect. Immun. 74, 6300-6309.
14. Breitbach, K., Köhler, J., and Steinmetz, I. (2008). Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycle. Trans. R. Soc. Trop. Med. Hyg. 102, S89-S94.
15. Breitbach, K., Wongprompitak, P., and Steinmetz, I. (2011). Distinct roles for nitric oxide in resistant C57BL/6 and susceptible BALB/c mice to control Burkholderia pseudomallei infection. BMC Immunol. 12,20. doi: 10.1186/1471-2172-12-20
16. Brett,P.,and Woods,D. E. (1996). Structural and immunological characterization of Burkholderia pseudomallei O-polysaccaride-flagellin protein conjugates. Infect. Immun 64, 2824-2828.
17. Brett, P. J., Burtnick, M. N., and Woods, D. E. (2003). The wbiA locus is required for the 2-O-acetylation of lipopolysaccharide expressed by Burkholderia pseudomallei and Burkholderia thailandensis. FEMS Microbiol. Lett. 218, 323-328.
18. Brett, P. J., Mah, D. C., and Woods, D. E. (1994). Isolation and characterization of Pseudomonas pseudomallei flagellin proteins. Infect. Immun. 62, 1914-1919.
19. Brown, A. E., Dance, D. A., Suputtamongkol, Y., Chaowagul, W., Kongchareon, S., Webster, H. K., and White, N. J. (1991). Immune cell activation in melioidosis: increased serum levels of interferon-gamma and soluble interleukin-2 receptors without change in soluble CD8 protein. J. Infect. Dis. 163, 1145-1148.
20. Cai, H., Yu, D. H., Hu, X. D., Li, S. X., and Zhu, Y. X. (2006). A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge. DNA Cell Biol. 25, 438-447.
21. Chanchamroen, S., Kewcharoenwong, C., Susaengrat, W., Ato, M., and Lertmemongkolchai, G. (2009). Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect. Immun. 77, 456-463.
22. Chaowagul, W., Suputtamongkol, Y., Dance, D. A., Rajchanuvong, A., Pattaraarechachai, J., and White, N. J. (1993). Relapse in melioidosis: incidence and risk factors. J. Infect. Dis. 168, 1181-1185.
23. Chaowagul, W., White, N. J., Dance, D. A., Wattanagoon, Y., Naigowit, P., Davis, T. M., Looareesuwan, S., and Pitakwatchara, N. (1989). Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J. Infect. Dis. 159, 890-899.
24. Charuchaimontri, C., Suputtamongkol, Y., Nilakul, C., Chaowagul, W., Chetchotisakd, P., Lertpatanasuwun, N., Intaranongpai, S., Brett, P. J., and Woods, D. E. (1999). Antilipopolysaccharide II: an antibody protective against fatal melioidosis. Clin. Infect. Dis. 29, 813-818.
25. Chen,Y.-S., Hsiao, Y.-S., Lin, H.-H., Liu, Y., and Chen, Y.-L. (2006a). CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect. Immun. 74, 1699-1705.
26. Chen,Y.-S., Hsiao,Y.-S., Lin, H.-H.,Yen, C.-M., Chen, S.-C., and Chen, Y.-L. (2006b). Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine 24, 750-758.
27. Cheng, A., and Currie, B. (2005). Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18, 383-416.
28. Cheng, A. C., Wuthiekanun, V., Limmathurotsakul, D., Chierakul, W., and Peacock, S. J. (2008). Intensity of exposure and incidence of melioidosis in Thai children. Trans. R. Soc. Trop. Med. Hyg. 102, S37-S39.
29. Chierakul, W., Wuthiekanun, V., Chaowagul, W., Amornchai, P., Cheng, A. C., White, N. J., Day, N. P. J., and Peacock, S. J. (2005). Disease severity and outcome of melioidosis in HIV coinfected individuals. Am. J. Trop. Med. Hyg. 73, 1165-1166.
30. Chrispal, A., Rajan, S. J., and Sathyendra, S. (2010). The clinical profile and predictors of mortality in patients with melioidosis in South India. Trop. Doct. 40, 36-38.
31. Clements, A., Jenney, A. W., Farn, J. L., Brown, L. E., Deliyannis, G., Hartland, E. L., Pearse, M. J., Maloney, M. B., Wesselingh, S. L., Wijburg, O. L., and Strugnell, R. A. (2008). Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections. Vaccine 26, 5649-5653.
32. Coban, C., Koyama, S., Takeshita, F., Akira, S., and Ishii, K. J. (2008). Molecular and cellular mechanisms of DNA vaccines. Hum. Vaccin. 4, 453-457.
33. Coffman, R. L., and Carty, J. (1986). A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J. Immunol. 136, 949-954.
34. Conlan, J. W., Shen, H., KuoLee, R., Zhao, X., and Chen, W. (2005). Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an αβ T cell-and interferon gamma-dependent mechanism. Vaccine 23, 2477-2485.
35. Currie, B. (2003). Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions. Eur. Respir. J. 22, 542-550.
36. Currie, B. J. (2008). Advances and remaining uncertainties in the epidemiology of Burkholderia pseudomallei and melioidosis. Trans. R. Soc. Trop.Med.Hyg.102, 225-227.
37. Currie, B. J., Fisher, D. A., Howard, D. M., Burrow, J. N., Lo, D., Selva-Nayagam, S., Anstey, N. M., Huffam, S. E., Snelling, P. L., Marks, P. J., Stephens, D. P., Lum, G. D., Jacups, S. P., and Krause, V. L. (2000). Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin. Infect. Dis. 31, 981-986.
38. Currie, B. J., and Jacups, S. P. (2003). Intensity of rainfall and severity of melioidosis, Australia. Emerg. Infect. Dis. 9, 1538-1542.
39. Currie, B. J., Jacups, S. P., Cheng, A. C., Fisher, D. A., Anstey, N. M., Huffam, S. E., and Krause, V. L. (2004). Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop. Med. Int. Health 9, 1167-1174.
40. Dance, D. A. B., Wuthiekanun, V., Chaowagul, W., and White, N. J. (1989). The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J. Antimicrob. Chemother. 24, 295-309.
41. Dannenberg, A. M. Jr., and Scott, E. M. (1958a). Melioidosis: pathogenesis and immunity in mice and hamsters. I. Studies with virulent strains of Malleomyces pseudomallei. J. Exp. Med. 107, 153-166.
42. Dannenberg, A. M. Jr., and Scott, E. M. (1958b). Melioidosis: pathogenesis and immunity in mice and hamsters. II. Studies with avirulent strains of Malleomyces pseudomallei. Am. J. Pathol. 34, 1099-1121.
43. Dannenberg, A. M. Jr., and Scott, E. M. (1960). Melioidosis: pathogenesis and immunity in mice and hamsters: III. Effect of vaccination with avirulent strains of Pseudomonas pseudomallei on the resistance to the establishment and the resistance to the progress of respiratory melioidosis caused by virulent strains; all-or-none aspects of this disease. J. Immunol. 84, 233-246.
44. Danzig, L. (2004). Meningococcal vaccines. Pediatr. Infect. Dis. J. 23, S285-S292.
45. Dennis,D. T.,Inglesby,T.V.,Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine,A. D., Friedlander,A. M., Hauer, J., Layton, M.,Lillibridge, S. R., McDade, J. E., Osterholm, M. T., OToole, T., Parker, G., Perl, T. M., Russell, P. K., Tonat, K., and for the Working Group in Civilian Biodefense. (2001). Tularemia as a biological weapon: medical and public health management. JAMA 285, 2763-2773.
46. Dorman, S. E., Gill, V. J., Gallin, J. I., and Holland, S. M. (1998). Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: case report and review of occurrences in the Americas. Clin. Infect. Dis. 26, 889-894.
47. Druar, C., Yu, F., Barnes, J. L., Okinaka, R. T., Chantratita, N., Beg, S., Stratilo, C. W., Olive, A. J., Soltes, G., Russell, M. L., Limmathurotsakul, D., Norton, R. E., Ni, S. X., Picking, W. D., Jackson, P. T., Stewart, D. I. H., Tsvetnitsky, V., Picking, W. L., Cherwonogrodzky, J. W., Ketheesan, N., Peacock, S. J., and Wiersma, E. J. (2008). Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents. FEMS Immunol. Med. Microbiol. 52, 78-87.
48. Dworkin, M. S., Ward, J. W., Hanson, D. L., Jones, J. L., and Kaplan, J. E. (2001). Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin. Infect. Dis. 32, 794-800.
49. Easton, A., Haque, A., Chu, K., Lukaszewski, R., and Bancroft, G. J. (2007). A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J. Infect. Dis. 195, 99-107.
50. Easton, A., Haque, A., Chu, K., Patel, N., Lukaszewski, R., Krieg, A. M., Titball,R.W.,and Bancroft,G. J. (2011). Combining vaccination and postex-posure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J. Infect. Dis. 204, 636-644.
51. Edelson,B. T.,and Unanue,E. R. (2000). Immunity to Listeria infection. Curr. Opin. Immunol. 12, 425-431.
52. Egan, A. M., and Gordon, D. L. (1996). Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect. Immun. 64, 4952-4959.
53. Ekchariyawat, P., Pudla, S., Limposuwan, K., Arjcharoen, S., Sirisinha, S., and Utaisincharoen, P. (2005). Burkholderia pseudomallei-induced expression of suppressor of cytokine signaling 3 and cytokine-inducible Src homology 2-containing protein in mouse macrophages: a possible mechanism for suppression of the response to gamma interferon stimulation. Infect. Immun. 73, 7332-7339.
54. Elvin, S., Healey, G., Westwood, A., Knight, S., Eyles, J., and Williamson, E. (2006). Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect. Immun. 74, 1706-1711.
55. Eskola, J. (2010). Foresight in medicine: current challenges with Haemophilus influenzae type b conjugate vaccines. J. Intern. Med. 267, 241-250.
56. Flynn,J.,and Chan,J. (2001). Immunology of tuberculosis. Annu. Rev. Immunol. 19, 93-129.
57. Friedland, J. S., Suputtamongkol, Y., Remick, D. G., Chaowagul, W., Strieter, R. M., Kunkel, S. L., White, N. J., and Griffin, G. E. (1992). Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect. Immun. 60, 2402-2408.
58. Fry, A. M., Zell, E. R., Schuchat, A., Butler, J. C., and Whitney, C. G. (2002). Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 21, 303-311.
59. Fulop, M., Mastroeni, P., Green, M., and Titball, R. W. (2001). Role of antibody to lipopolysaccharide in protection against low-and high-virulence strains of Francisella tularensis. Vaccine 19, 4465-4472.
60. Garmory, H. S., and Titball, R. W. (2004). ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect. Immun. 72, 6757-6763.
61. Gilks, C. F., Ojoo, S. A., Ojoo, J. C., Brindle, R. J., Paul, J., Batchelor, B. I., Kimari, J. N., Newnham, R., Bwayo, J., Plummer, F. A., and Warrell, D. A. (1996). Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 347, 718-723.
62. Govan, B., and Ketheesan, N. (2004). Exposure to Burkholderia pseudomallei induces cell-mediated immunity in healthy individuals. Clin. Microbiol. Infect. 10, 585-587.
63. Griffin, K. F., Oyston, P. C., and Titball, R. W. (2007). Francisella tularensis vaccines. FEMS Immunol. Med. Microbiol. 49, 315-323.
64. Guard, R. W., Khafagi, F. A., Brigden, M. C., and Ashdown, L. R. (1984). Melioidosis in far north Queensland: a clinical and epidemiological review of twenty cases. Am. J. Trop. Med. Hyg. 33, 467-473.
65. Haque, A., Easton, A., Smith, D., OGarra, A., Van Rooijen, N., Lert-memongkolchai, G., Titball, R. W., and Bancroft, G. J. (2006a). Role of T cells in innate and adaptive immunity against murine Burkholderia pseudomallei infection. J. Infect. Dis. 193, 370-379.
66. Haque, A., Chu, K., Easton, A., Stevens, M. P.,Galyov,E. E.,Atkins,T.,Titball, R., and Bancroft, G. J. (2006b). A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J. Infect. Dis. 194, 1241-1248.
67. Hara, Y., Mohamed, R., and Nathan, S. (2009). Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets. PLoS ONE 4, e6496. doi: 10.1371/journal.pone.0006496
68. Harland, D., Dassa, E., Titball, R., Brown, K., and Atkins, H. (2007a). ATP-binding cassette systems in Burkholderia pseudomallei and Burkholderia mallei. BMC Genomics 8, 83. doi: 10.1186/1471-2164-8-83
69. Harland, D. N., Chu, K., Haque, A., Nelson, M., Walker, N. J., Sarkar-Tyson, M., Atkins, T. P., Moore, B., Brown, K. A., Bancroft, G., Titball, R. W., and Atkins, H. S. (2007b). Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis. Infect. Immun. 75, 4173-4178.
70. Hasselbring, B. M., Patel, M. K., and Schell, M. A. (2011). Dictyostelium discoideum asamodel system for identification of Burkholderia pseudomallei virulence factors. Infect. Immun. 79, 2079-2088.
71. Healey, G. D., Elvin, S. J., Morton, M., and Williamson, E. D. (2005). Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect. Immun. 73, 5945-5951.
72. Henderson, A., Propst, K., Kedl, R., and Dow, S. (2011). Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity. Vaccine 29, 5304-5312.
73. Henderson, I. R., Navarro-Garcia, F., Desvaux, M., Fernandez, R. C., and AlaAldeen, D. (2004). Type V protein secretion pathway: the autotransporter story. Microbiol. Mol. Biol. Rev. 68, 692-744.
74. Hewlett, E. L. (1997). Preparation and composition of acellular pertussis vaccines. Consideration of potential effects on vaccine efficacy. Dev. Biol. Stand. 89, 143-151.
75. Higgins, S. C., Jarnicki, A. G., Lavelle, E. C., and Mills, K. H. G. (2006). TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177, 7980-7989.
76. Hii, C. S., Sun, G. W., Goh, J. W. K., Lu, J., Stevens, M. P., and Gan, Y. H. (2008). Interleukin-8 induction by Burkholderia pseudomallei can occur without Toll-like receptor signaling but requires a functional type III secretion system. J. Infect. Dis. 197, 1537-1547.
77. Hill, D. R., Ford, L., and Lalloo, D. G. (2006). Oral cholera vaccines: use in clinical practice. Lancet Infect. Dis. 6, 361-373.
78. Ho, M., Schollaardt, T., Smith, M. D., Perry, M. B., Brett, P. J., Chaowagul, W., and Bryan, L. E. (1997). Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect. Immun. 65, 3648-3653.
79. Hoover, D. R., Saah, A. J., Bacellar, H., Phair, J., Detels, R., Anderson, R., Kaslow, R. A., and The Multicenter AIDS Cohort Study (1993). Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N. Engl. J. Med. 329, 1922-1926.
80. Hoppe, I., Brenneke, B., Rohde, M., Kreft, A., Häußler, S., Reganzer-rowski, A., and Steinmetz, I. (1999). Characterization of a murine model of melioidosis: comparison of different strains of mice. Infect. Immun. 67, 2891-2900.
81. Hornick, R. B., and Eigelsbach, H. T. (1966). Aerogenic immunization of man with live Tularemia vaccine. Microbiol. Mol. Biol. Rev. 30, 532-538.
82. Howe, C., Sampath,A., and Spotnitz, M. (1971). The pseudomallei group: a review. J. Infect. Dis. 124, 598-606.
83. Iliukhin, V. I., Senina, T. V., Plekhanova, N. G., Antonov, V. A., Merinova, L. K., and Seimova, I. K. (2002). Burkholderia thailandensis: biological properties, identification and taxonomy. Mol. Gen. Mikrobiol. Virusol. 1, 7-11.
84. Inglesby,T.V.,Dennis,D. T.,Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine,A. D., Friedlander,A. M., Hauer, J., Koerner, J. F., McDade, J., Osterholm, M. T., O., Toole, T., Parker, G., Perl, T. M., Russell, P. K., SchochSpana, M., Tonat, K., and for the Working Group in Civilian Biodefense. (2000). Plague as a biological weapon: medical and public health management. JAMA 283, 2281-2290.
85. Inglesby, T. V., OToole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., McDade, J., Osterholm, M. T., Parker, G., Perl, T. M., Russell, P. K., Tonat, K., and for the Working Group in Civilian Biodefense. (2002). Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287, 2236-2252.
86. Ivanoff, B., Levine, M. M., and Lambert, P. H. (1994). Vaccination against typhoid fever: present status. Bull. World Health Organ. 72, 957-971.
87. Janeway, C. A., and Medzhitov, R. (2002). Innate immune recognition. Annu. Rev. Immunol. 20, 197-216.
88. Janeway, C.A. Jr., Murphy, K., Travers, P., and Walport, M. (2008). Janeways Immunobiology: T Cell-Mediated Immunity, Chapter 8, 7th Edn. New York: Garland Science, 340-341.
89. Jones, A., DeShazer, D., and Woods, D. (1997). Identification and characterization of a two-component regulatory system involved in invasion of eukaryotic cells and heavy-metal resistance in Burkholderia pseudomallei. Infect. Immun. 65, 4972-4977.
90. Jones, C. (2005). Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An. Acad. Bras. Cienc. 77, 293-324.
91. Jones, S., Ellis, J., Russell, P., Griffin, K., and Oyston, P. (2002). Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J. Med. Microbiol. 51, 1055-1062.
92. Kanaphun, P., Thirawattanasuk, N., Suputtamongkol, Y., Naigowit, P., Dance, D. A., Smith, M. D., and White, N. J. (1993). Serology and carriage of Pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in north-east Thailand. J. Infect. Dis. 167, 230-233.
93. Kaufmann, S. H. E., Hussey, G., and Lambert, P.-H. (2010). New vaccines for tuberculosis. Lancet 375, 2110-2119.
94. Ketheesan, N., Barnes, J. L., Ulett, G. C., VanGessel, H. J., Norton, R. E., Hirst, R. G., and LaBrooy, J. T. (2002). Demonstration of a cell-mediated immune response in melioidosis. J. Infect. Dis. 186, 286-289.
95. Lauw, F. N., Simpson, A. J., Prins, J. M., Smith, M. D., Kurimoto, M., van Deventer, S. J., Speelman, P., Chaowagul, W., White, N. J., and van der Poll, T. (1999). Elevated plasma concentrations of interferon (IFN)-gamma and the IFN-gamma-inducing cytokines interleukin (IL)-18, IL-12, and IL-15 in severe melioidosis. J. Infect. Dis. 180, 1878-1885.
96. Lazzaroni, S. M., Barnes, J. L., Williams, N. L., Govan, B. L., Norton, R. E., LaBrooy, J. T., and Ketheesan, N. (2008). Seropositivity to Burkholderia pseudomallei does not reflect the development of cell-mediated immunity. Trans. R. Soc. Trop. Med. Hyg. 102, S66-S70.
97. Leakey, A. K., Ulett, G. C., and Hirst, R. G. (1998). BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb. Pathog. 24, 269-275.
98. Lertmemongkolchai, G., Cai, G., Hunter, C. A., and Bancroft, G. J. (2001). Bystander activation of CD8+ T cells contributes to the rapid production of IFN-gamma in response to bacterial pathogens. J. Immunol. 166, 1097-1105.
99. Lever, M. S., Michelle, N., Anthony, J. S., Richard, J. B., and Andrew, J. H. S. (2009). Experimental acute respiratory Burkholderia pseudomallei infection in BALB/c mice. Int. J. Exp. Pathol. 90, 16-25.
100. Liljeqvist, S., and Ståhl, S. (1999). Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J. Biotechnol. 73, 1-33.
101. Limmathurotsakul, D., Chaowagul, W., Chierakul, W., Stepniewska, K., Maharjan, B., Wuthiekanun, V., White, N., Day, N., and Peakcock, S. (2006). Risk factors for recurrent melioidosis. Clin. Infect. Dis. 43, 979-986.
102. Limmathurotsakul, D., Wuthiekanun, V., Chantratita, N., Wongsuvan, G., Thanwisai, A., Biaklang, M., Tumapa, S., Lee, S., Day, N. P. J., and Peacock, S. J. (2007). Simultaneous infection with more than one strain of Burkholderia pseudomallei is uncommon in human melioidosis. J. Clin. Microbiol. 45, 3830-3832.
103. Liu, B., Koo, G. C., Yap, E. H., Chua, K. L., and Gan, Y.-H. (2002). Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect. Immun. 70, 504-511.
104. Lu, S. (2009). Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21, 346-351.
105. Magalhaes, I., Sizemore, D. R., Ahmed, R. K., Mueller, S., Wehlin, L., Scanga, C., Weichold, F., Schirru, G., Pau, M. G., Goudsmit, J., Kühlmann-Berenzon, S., Spångberg, M., Andersson, J., Gaines, H., Thorstensson, R., Skeiky, Y. A. W., Sadoff, J., and Maeurer, M. (2008). rBCG induces strong antigen-specific T cell responses in Rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS ONE 3, e3790. doi: 10.1371/journal.pone.0003790
106. Maharjan, B., Chantratita, N., Vesaratchavest, M., Cheng, A., Wuthiekanun, V., Chierakul, W., Chaowagul, W., Day, N. P. J., and Peacock, S. J. (2005). Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse. J. Clin. Microbiol. 43, 6032-6034.
107. Martineau, A. R., Newton, S. M., Wilkinson, K. A., Kampmann, B., Hall, B. M., Nawroly, N., Packe, G. E., Davidson, R. N., Griffiths, C. J., and Wilkinson, R. J. (2007). Neutrophil-mediated innate immune resistance to mycobacteria. J. Clin. Invest. 117, 1988-1994.
108. Matsuura, M., Kawahara, K., Ezaki, T., and Nakano, M. (1996). Biological activities of lipopolysaccharide of Burkholderia (Pseudomonas) pseudomallei. FEMS Microbiol. Lett. 137, 79-83.
109. McEniry, D. W., Gillespie, S. H., and Felmingham, D. (1988). Susceptibility of Pseudomonas pseudomallei to new betalactam and aminoglycoside antibiotics. J. Antimicrob. Chemother. 21, 171-175.
110. McShane, H., Pathan, A. A., Sander, C. R., Keating, S. M., Gilbert, S. C., Huygen, K., Fletcher, H. A., and Hill, A. V. S. (2004). Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10, 1240-1244.
111. Menard, L. C., Minns, L. A., Darche, S., Mielcarz, D. W., Foureau, D. M., Roos, D., Dzierszinski, F., Kasper, L. H., and BuzoniGatel, D. (2007). B cells amplify IFN-gamma production by T cells via a TNF-alpha-mediated mechanism. J. Immunol. 179, 4857-4866.
112. Mitus, A., Holloway, A., Evans, A. E., and Enders, J. F. (1962). Attenuated measles vaccine in children with acute leukemia. Am. J. Dis. Child. 103, 413-418.
113. Monafo, W. J., Haslam, D. B., Roberts, R. L., Zaki, S. R., Bellini, W. J., and Coffin, C. M. (1994). Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J. Pediatr. 124, 273-276.
114. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., and Coffman, R. L. (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357.
115. Nelson, M., Prior, J. L., Lever, M. S., Jones, H. E., Atkins, T. P., and Titball, R. W. (2004). Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis. J. Med. Microbiol. 53, 1177-1182.
116. Ngugi, S. A., Ventura, V. V., Qazi, O., Harding, S. V., Kitto, G. B., Estes, D. M., Dell, A., Titball, R. W., Atkins, T. P., Brown, K. A., Hitchen, P. G., and Prior, J. L. (2010). Lipopolysaccharide from Burkholderia thailandensis E264 provides protection in a murine model of melioidosis. Vaccine 28, 7551-7555.
117. Nieves,W., Heang, J.,Asakrah, S., Höner zu Bentrup, K., Roy, C. J., and Morici, L. A. (2010). Immunospecific responses to bacterial elongation factor Tu during Burkholderia infection and immunization. PLoS ONE 17, e14361. doi: 10.1371/journal.pone.0014361
118. Novem, V., Shui, G., Wang, D., Bendt, A. K., Sim, S. H., Liu, Y., Thong, T. W., Sivalingam, S. P., Ooi, E. E., Wenk, M. R., and Tan, G. (2009). Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clin. Vaccine Immunol. 16, 1420-1428.
119. Perrone, L. A., Ahmad, A., Veguilla, V., Lu, X., Smith, G., Katz, J. M., Pushko, P., and Tumpey, T. M. (2009). Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 83, 5726-5734.
120. Phair, J., Munoz, A., Detels, R., Kaslow, R., Rinaldo, C., and Saah, A. (1990). The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N.Engl.J.Med. 322, 161-165.
121. Piggott, J. A., and Hochholzer, L. (1970). Human melioidosis. A histopathologic study of acute and chronic melioidosis. Arch. Pathol. 90, 101-111.
122. Pilatz, S., Breitbach, K., Hein, N., Fehlhaber, B., Schulze, J., Brenneke, B., Eberl, L., and Steinmetz, I. (2006). Identification of Burkholderia pseudomallei genes required for the intracellular life cycle and in vivo virulence. Infect. Immun. 74, 3576-3586.
123. Pirofski, L. A., and Casadevall, A. (1998). Use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11, 1-26.
124. Plotkin, S. A. (2009). Vaccines: the fourth century. Clin. Vaccine Immunol. 16, 1709-1719.
125. Preston, M. J., Gerceker, A. A., Koles, N. L., Pollack, M., and Pier, G. B. (1997). Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Invest. Ophthalmol. Vis. Sci. 38, 1418-1425.
126. Puthucheary, S. D., Parasakthi, N., and Lee, M. K. (1992). Septicaemic melioidosis: a review of 50 cases from Malaysia. Trans. R. Soc. Trop. Med. Hyg. 86, 683-685.
127. Qazi, O., Prior, J. L., Judy, B. M., Whitlock, G. C., Kitto, G. B., Torres, A. G., Estes, D. M., and Brown, K. A. (2008). Sero-characterization of lipopolysaccharide from Burkholderia thailandensis. Trans. R. Soc. Trop. Med. Hyg. 102, S58-S60.
128. Radosevic, K., Wieland, C. W., Rodriguez, A., Weverling, G. J., Mintardjo, R., Gillissen, G., Vogels, R., Skeiky, Y. A. W., Hone, D. M., Sadoff, J. C., van der Poll, T., Havenga, M., and Goudsmit, J. (2007). Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect. Immun. 75, 4105-4115.
129. Ramsay, S. C., Ketheesan, N., Norton, R., Watson, A. M., and LaBrooy, J. (2002). Peripheral blood lymphocyte subsets in acute human melioidosis. Eur. J. Clin. Microbiol. Infect. Dis. 21, 566-568.
130. Razak, C. E., Ismail, G., Embim, N., and Omar, O. (1986). Protection studies using whole cells and partially purified toxic material (PPTM) of Pseudomonas pseudomallei. Malays. Appl. Biol. 15, 105.
131. Renella, R., Perez, J. M., Chollet-Martin, S., Sarnacki, S., Fischer, A., Blanche, S., Casanova, J. L., and Picard, C. (2006). Burkholderia pseudomallei infection in chronic granulomatous disease. Eur. J. Pediatr. 165, 175-177.
132. Sander, C. R., Pathan, A. A., Beveridge, N. E. R., Poulton, I., Minassian, A., Alder, N., Van Wijgerden, J., Hill, A. V. S., Gleeson, F. V., Davies, R. J. O., Pasvol, G., and McShane, H. (2009). Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am. J. Respir. Crit. Care Med. 179, 724-733.
133. Santanirand, P., Harley, V., Dance, D., Drasar, B., and Bancroft, G. J. (1999). Obligatory role of gamma interferon for host survival in a murine model of infection with B. pseudomallei. Infect. Immun. 67, 3593-3600.
134. Santanirand, P., Harley, V. S., Dance, D. A., Raynes, J. G., Drasar, B. S., and Bancroft, G. J. (1997). Interferon-gamma mediates host resistance in a murine model of melioidosis. Biochem. Soc. Trans. 25, 287S.
135. Santosuosso, M., McCormick, S., Zhang, X., Zganiacz, A., and Xing, Z. (2006). Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74, 4634-4643.
136. Sarkar-Tyson, M., Smither, S. J., Harding, S. V., Atkins, T. P., and Tit-ball, R. W. (2009). Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders. Vaccine 27, 4447-4445.
137. Sarkar-Tyson, M., Thwaite, J. E., Harding, S. V., Smither, S. J., Oyston, P. C. F., Atkins, T. P., and Titball, R. W. (2007). Polysaccharides and virulence of Burkholderia pseudomallei. J. Med. Microbiol. 56, 1005-1010.
138. Scapini, P., Lapinet-Vera, J. A., Gasperini, S., Calzetti, F., Bazzoni, F., and Cassatella, M. A. (2000). The neutrophil as a cellular source of chemokines. Immunol. Rev. 177, 195-203.
139. Segal, A. W. (2004). How neutrophils kill microbes. Annu. Rev. Immunol. 23, 197-223.
140. Sharma, S. K., Mohan, A., and Kadhiravan, T. (2005). HIV-TB coinfection: epidemiology, diagnosis and management. Indian J. Med. Res. 121, 550-567.
141. Simpson, A. J., Smith, M. D., Weverling, G. J., Suputtamongkol, Y., Angus, B. J., Chaowagul, W., White, N. J., van Deventer, S. J., and Prins, J. M. (2000). Prognostic value of cytokine concentrations (tumor necrosis factor-alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J. Infect. Dis. 181, 621-625.
142. Simpson, A. J., Suputtamongkol, Y., Smith, M. D., Angus, B. J., Rajanuwong, A., Wuthiekanun, V., Howe, P. A., Walsh, A. L., Chaowagul, W., and White, N. J. (1999). Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis. 29, 381-387.
143. Smith, M. D., Angus, B. J., Wuthiekanun, V., and White, N. J. (1997). Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect. Immu. 65, 4319-4321.
144. Sprague,L. D.,and Neubauer,H. (2004). Melioidosis in animals: a review on epizootiology, diagnosis and clinical presentation. J. Vet. Med. Ser. B Infect. Dis. Vet. Public Health 51, 305-320.
145. Stevens, M. P., Haque, A., Atkins, T., Hill, J., Wood, M. W., Easton, A., Nelson, M., Underwood-Fowler, C., Titball, R. W., Bancroft, G. J., and Galyov, E. E. (2004). Attenuated virulence and protective efficacy of a Burkholderia pseudomallei bsa type III secretion mutant in murine models of melioidosis. Microbiology 150, 2669-2676.
146. Su, Y.-C., Wan, K.-L., Mohamed, R., and Nathan, S. (2010). Immunization with the recombinant Burkholderia pseudomallei outer membrane protein Omp85 induces protective immunity in mice. Vaccine 28, 5005-5011.
147. Suputtamongkol, Y., Chaowagul, W., Chetchotisakd, P., Lertpatanasuwun, N., Intaranongpai, S., Ruchutrakool, T., Budhsarawong, D., Mootsikapun, P.,Wuthiekanun,V., Teerawatasook, N., and Lulitanond, A. (1999). Risk factors for melioidosis and bacteremic melioidosis. Clin. Infect. Dis. 29, 408-413.
148. Suputtamongkol, Y., Kwiatkowski, D., Dance, D. A., Chaowagul, W., and White, N. J. (1992). Tumor necrosis factor in septicemic melioidosis. J. Infect. Dis. 165, 561-564.
149. Tan, G.-Y. G., Liu, Y., Sivalingam, S. P., Sim, S.-H., Wang, D., Paucod, J.-C., Gauthier, Y., and Ooi, E.-E. (2008). Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. J. Med. Microbiol. 57, 508-515.
150. Tanphaichitra, D., and Srimuang, S. (1984). Cellular immunity (T-cell subset using monoclonal antibody) in tuberculosis, melioidosis, pasteurellosis, penicilliosis; and role of levamisole and isoprinosine. Dev. Biol. Stand. 57, 117-123.
151. Taylor, P. R., Martinez-Pomares, L., Stacey, M., Lin, H. H., Brown, G. D., and Gordon, S. (2005). Macrophage receptors and immune recognition. Annu. Rev. Immunol. 23, 901-944.
152. Thomsen, A. R., Johansen, J., Marker, O., and Christensen, J. P. (1996). Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice. J. Immunol. 157, 3074-3080.
153. Tippayawat, P., Saenwongsa, W., Mahawantung, J., Suwannasaen, D., Chetchotisakd, P., Limmathurot-sakul, D., Peacock, S. J., Felgner, P. L., Atkins, H. S., Titball, R. W., Bancroft, G. J., and Lertmemongkolchai, G. (2009). Phenotypic and functional characterization of human memory T cell responses to Burkholderia pseudomallei. PLoS Negl. Trop. Dis. 3, e407. doi: 10.1371/journal.pntd.0000407
154. Titball, R. W. (2008). Vaccines against intracellular bacterial pathogens. Drug Discov. Today 13, 596-600.
155. Titball, R. W., Russell, P., Cuccui, J., Easton, A., Haque, A., Atkins, T., Sarkar-Tyson, M., Harley, V., Wren, B., and Bancroft, G. J. (2008). Burkholderia pseudomallei: animal models of infection. Trans. R. Soc. Trop. Med. Hyg. 102, S111-S116.
156. Trakulsomboon, S., Pitt, T. L., and Dance, D. A. (1994). Molecular typing of Pseudomonas pseudomallei from imported primates in Britain. Vet. Rec. 135, 65-66.
157. Ulett, G. C., Ketheesan, N., and Hirst, R. G. (2000a). Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect. Immun. 68, 2034-2042.
158. Ulett, G. C., Ketheesan, N., and Hirst, R. G. (2000b). Proinflammatory cytokine mRNA responses in experimental Burkholderia pseudomallei infection in mice. Acta Trop. 74, 229-234.
159. Utaisincharoen, P., Anuntagool, N., Arjcharoen, S., Lengwehasatit, I., Limposuwan, K., Chaisuriya, P., and Sirisinha, S. (2004). Burkholderia pseudomallei stimulates low interleukin-8 production in the human lung epithelial cell line A549. Clin. Exp. Immunol. 138, 61-65.
160. Utaisincharoen, P., Tangthaworn-chaikul, N., Kespichayawattana, W., Chaisuriya, P., and Sirisinha, S. (2001). Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing. Microbiol. Immunol. 45, 307-313.
161. Vasu, C., Vadivelu, J., and Puthucheary, S. D. (2003). The humoral immune response in melioidosis patients during therapy. Infection 31, 24-30.
162. Verreck, F. A. W., Vervenne, R. A. W., Kondova, I., van Kralingen, K. W., Remarque, E. J., Braskamp, G., van der Werff, N. M., Kersbergen, A., Ottenhoff, T. H. M., Heidt, P. J., Gilbert, S. C., Gicquel, B., Hill, A. V. S., Martin, H., McShane, H., and Thomas, A. W. (2009). MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in Rhesus macaques. PLoS ONE 4, e5264. doi: 10.1371/journal.pone. 0005264
163. Wand, M., Muller, C., Titball, R., and Michell, S. (2011). Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis. BMC Microbiol. 11, 11. doi: 10.1186/1471-2180-11-11
164. Wells, T. J., Tree, J. J., Ulett, G. C., and Schembri, M. A. (2007). Auto-transporter proteins: novel targets at the bacterial cell surface. FEMS Microbiol. Lett. 274, 163-172.
165. White, N. (2003). Melioidosis. Lancet 361, 1715-1722. Wiersinga
166. Wiersinga,W.,vanderPoll,T.,White, N., Day,N.,and Peacock,S. (2006). Melioidosis:insightsinto the pathogenicityof Burkholderia pseudomallei. Nat.Rev.Microbiol. 4, 272-282.
167. Wiersinga, W. J., Dessing, M. C., Kager, P. A., Cheng, A. C., Limmathurotsakul, D., Day, N. P., Dondorp, A. M., van der Poll, T., and Peacock, S. J. (2007a). High-throughput mRNA profiling characterizes the expression of inflammatory molecules in sepsis caused by Burkholderia pseudomallei. Infect. Immun. 75, 3074-3079.
168. Wiersinga, W. J., Wieland, C. W., Dessing, M. C., Chantratita, N., Cheng, A. C., Limmathurotsakul, D., Chierakul, W., Leendertse, M., Florquin, S., de Vos, A. F.,White, N., Dondorp, A. M., Day, N. P., Peacock, S. J., and van der Poll, T. (2007b). Toll-like receptor 2 impairs host defense in Gram-negative sepsis caused by Burkholderia pseudomallei (melioidosis). PLoS Med. 4, e248. doi: 10.1371/journal.pmed.0040248
169. Wiersinga, W. J., Wieland, C. W., van der Windt, G. J. W., de Boer, A., Florquin, S., Dondorp, A., Day, N. P., Peacock, S. J., and van der Poll, T. (2007c). Endogenous interleukin-18 improves the early antimicrobial host response in severe melioidosis. 75, 3739-3746.
170. Wiersinga, W. J., and van der Poll, T. (2009). Immunity to Burkholderia pseudomallei. Curr. Opin. Infect. Dis. 22, 102-108.
171. Wiersinga, W. J., Wieland, C. W., Roelofs, J. J. T. H., and van der Poll, T. (2008). MyD88 dependent signaling contributes to protective host defense against Burkholderia pseudomallei. PLoS ONE 3, e3494. doi: 10.1371/journal.pone. 0003494
172. Williamson, E. D. (2009). Plague. Vaccine 27, D56-D60.
173. Wong, K. T., Puthucheary, S. D., and Vadivelu, J. (1995). The histopathology of human melioidosis. Histopathology 26, 51-55.